title: Phenotype alteration in colon carcinoma cells: effect of in vivo passage?
abstract: A panel of rat colon adenocarcinoma cell lines (the Per series) were used to investigate the phenotype and karyotype changes induced by in vivo passage in the subcutis of athymic nude mice. One poorly and one well-differentiated tumor cell line were serially passaged through the athymic nude mouse and then back to the syngeneic rat host. Each of the primary and xenograft cell lines expressed fetal crypt cell ("CaCo") antigens. The well differentiated primary and xenograft lines (Per305, Per305N1, and Per305N2a) were different in each of their growth factor responsiveness in vitro [i.e. epidermal growth factor (EGF), bombesin, vasoactive intestinal peptide], their EGF receptor expression, their secretion of transforming growth factor-alpha, and their exhibition of anchorage independent (A-I) growth capabilities. The poorly differentiated primary and xenograft cell lines were also different but were all capable of A-I growth; their responsiveness to exogenous growth factor stimulation decreased with progressive in vivo passage, as did their basal unstimulated proliferation rate. Cytogenetic alterations detected were those associated with clinical specimens from various stages of malignancy, i. e. aneuploidy, structural aberrations, and marker chromosomes. Genetic and mitogenic individuality of each line demonstrated the diversity of the growth control mechanisms in neoplasms at different stages of progression.
authors.affiliation: University Department of Surgery, Queen Elizabeth II Medical Centre, Nedlands, Western Australia.
authors.forename: M A
authors.initials: MA
authors.lastname: Maley
authors.forename: A K
authors.initials: AK
authors.lastname: House
authors.forename: D J
authors.initials: DJ
authors.lastname: Jenkyn
authors.forename: G
authors.initials: G
authors.lastname: Sterrett
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology*; D000818:Animals; D014408:Biomarkers, Tumor; D001839:Bombesin / Q000494:pharmacology; D003110:Colonic Neoplasms / Q000378:metabolism / Q000473:pathology*; D004815:Epidermal Growth Factor / Q000494:pharmacology; D066246:ErbB Receptors / Q000378:metabolism; D007621:Karyotyping; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010641:Phenotype; D018004:Receptors, Bombesin; D017981:Receptors, Neurotransmitter / Q000378:metabolism; D016211:Transforming Growth Factor alpha / Q000096:biosynthesis; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
chemical_list: D014408:Biomarkers, Tumor; D018004:Receptors, Bombesin; D017981:Receptors, Neurotransmitter; D016211:Transforming Growth Factor alpha; D014660:Vasoactive Intestinal Peptide; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D001839:Bombesin